SAN
DIEGO, July 31, 2024 /PRNewswire/ -- Cortechs.ai
is proud to announce that it has received a 3-year, multimillion
dollar NIH grant. Cortechs.ai will use the grant to support the
development of additional analysis software to automatically detect
and quantify the Amyloid Related Imaging Abnormalities (ARIA)
throughout the treatment of Alzheimer's patients to monitor the
effects of the therapeutic intervention and to improve patient
management.
"Cortechs.ai is not only committed to driving commercial
excellence with our product portfolio, but also we are equally
dedicated to driving research that delivers key values to patients
and clinicians alike. This ARIA grant signifies our commitment",
says Kyle Frye, CEO.
Cortechs.ai pioneered NeuroQuant, a volumetric analysis software
solution for various neurological disorders, and the latest
510k-pending NeuroQuant update
supports identification and evaluation of cerebral microhemorrhages
and vasogenic edema in patients with ARIA.
Dr. Aziz Ulug, the principal
investigator of this study, says "With the recent FDA approval of
drugs that target amyloid deposits, brain imaging becomes an
indispensable tool to monitor treatment related changes and
abnormalities in Alzheimer's patients undergoing therapy. Our new
research grant will enhance our existing products and continue our
commitment for helping patients and families coping with
Alzheimer's disease."
About Cortechs.ai
Cortechs.ai is a leader in AI applications in radiology.
Cortechs.ai uses cutting-edge technologies in medical imaging to
revolutionize disease screening and early detection so patients can
enjoy longer, healthier lives. The company develops and markets
breakthrough medical device software that quantifies and tracks
neurodegenerative diseases, and assists in the detection of
clinically significant cancer. Cortechs.ai's industry-leading brain
imaging software provides radiologists, neurologists, oncologists,
and clinical researchers worldwide with a convenient and
cost-effective way to quantify brain structures for assessing
Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma,
and other brain abnormalities. The company has FDA-cleared products
for use in helping the diagnosis and follow-up of neurodegenerative
and traumatic brain conditions, as well as prostate cancer. Please
visit www.cortechs.ai for further information and follow us on
Twitter, LinkedIn, and Facebook.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cortechsai-receives-a-new-nih-grant-for-aria-detection-in-alzheimers-disease-302210165.html
SOURCE Cortechs.ai